Literature DB >> 28499171

Quinazoline based α1-adrenoreceptor antagonists with potent antiproliferative activity in human prostate cancer cell lines.

Valentina Maestri1, Andrea Tarozzi2, Elena Simoni1, Antonio Cilia3, Elena Poggesi3, Marina Naldi4, Benedetta Nicolini2, Letizia Pruccoli2, Michela Rosini1, Anna Minarini5.   

Abstract

New α1-adrenoreceptor (α1-AR) antagonists related to prazosin and doxazosin were synthesized by replacing piperazine ring with (S)- or (R)-3-aminopiperidine. Binding studies indicated that the S configuration at the 3-C position of the piperidine ring is crucial for an optimal interaction of the compounds at all three α1-AR subtypes. Quinazolines 9 and 10, bearing a quinone ring on the lateral chain, exhibited also potent antiproliferative activity in LNCaP androgen-sensitive prostate cancer cell lines, higher than that of doxazosin. Compound 10 increased apoptosis, in terms of DNA fragmentation, without triggering cell necrosis. The prooxidant activity found in compound 10 may underlie its ability to inhibit cell proliferation in synergy with the effect mediated by α1-AR antagonism. Due to its better biological profile compared to doxazosin for LNCaP cell line, compound 10 might be a valuable lead compound for the design of new prostate antitumor agents.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antiproliferative activity; DNA fragmentation; Quinazoline; Quinone; α(1)-Adrenoreceptor antagonist

Mesh:

Substances:

Year:  2017        PMID: 28499171     DOI: 10.1016/j.ejmech.2017.05.003

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  1 in total

1.  A Pilot retrospective analysis of alpha-blockers on recurrence in men with localised prostate cancer treated with radiotherapy.

Authors:  Jordan Hart; Briohny Spencer; Catherine M McDermott; Russ Chess-Williams; Donna Sellers; David Christie; Shailendra Anoopkumar-Dukie
Journal:  Sci Rep       Date:  2020-05-18       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.